Semaglutide — the drug known by the brand names Ozempic and Wegovy — significantly improves liver biochemistry in patients with non-alcoholic fatty liver disease (NAFLD/NASH). That's the conclusion of a fresh meta-analysis pooling six randomized clinical trials with 1,980 participants. The price of the effect: an increased rate of nausea, diarrhea and vomiting.
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat in liver cells in people who don't abuse alcohol. It's estimated to affect about 30.2% of adults worldwide and can progress to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. To date no drug has been approved by the FDA for NAFLD treatment — the foundation of therapy remains weight loss and physical activity.
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that became a sensation as a weight-loss drug. An international group (Hassan et al.) ran a systematic review under the PRISMA protocol with PROSPERO registration. They searched PubMed, Scopus, Embase, Cochrane CENTRAL and ClinicalTrials.gov through January 2026 and selected 6 RCTs comparing semaglutide (oral or injectable) against placebo or active control in adults with NAFLD/NASH. Total — 1,980 participants. Effects were pooled using random-effects models (R 4.4.2), with effect sizes for transaminases reported as standardized mean differences (SMD).
Semaglutide significantly reduced both key markers of liver injury:
| Marker | SMD (95% CI) | p-value | Interpretation |
|---|---|---|---|
| ALT (alanine aminotransferase) | −0.74 (−1.11 to −0.36) | 0.0001 | medium-to-large effect |
| AST (aspartate aminotransferase) | −0.63 (−1.01 to −0.24) | 0.0014 | medium effect |
For context: an SMD of 0.2 is a small effect, 0.5 is medium and 0.8 is large. The values here land in the medium-to-large range — a clinically meaningful drop in transaminases, the biochemical markers of inflammation and hepatocyte damage.
Key takeaway: in people with fatty liver disease, semaglutide substantially reduces the biochemical signs of disease activity. This is consistent with the drug's known effects on weight loss and insulin sensitivity — the two main drivers of NAFLD.
However, data for pooling "complete NASH resolution" (disappearance of inflammation on biopsy) was insufficient — the authors couldn't run that analysis. So we see improved blood work, but can't yet speak confidently about histological reversal of disease.
If you have hepatic steatosis on ultrasound or elevated ALT/AST against a background of overweight or diabetes, this study adds another argument that GLP-1 agonists (semaglutide, liraglutide) are not just "weight-loss drugs" — they're tools with a direct metabolic effect on the liver.
This is a meta-analysis of a preprint, not a final journal publication. Several limitations:
⚠ This is a preprint — the article is hosted on Research Square and hasn't yet been peer-reviewed. Numbers may shift after peer review. Don't use this material as a clinical recommendation: discuss any therapy changes with your treating physician.
NutriAI Pro is a Telegram Mini App: snap a photo of your meal — AI returns calories and macros in 3 seconds. Free tier: 5 analyses per day.
Open @botnutraibot →